This study aims to analyze whether the high-fat diet decreases serum TNF-α and breast tumor area on benzopyrene induced mice (Mus musculus). This study was a true experimental with the randomized posttest-only control group design using 36 female mice (Mus musculus), 3-4 months age, 25 ± 5 grams. Mice were induced with benzopyrene (BZP) subcutaneously with a dose of 0.3mg/20gBB/day for 14 days in the right breast area, then randomly divided into 6 groups, K1 (negative control group, given standard feed), K2 (positive control group, standard feed), K3 (high-fat diet with a ratio of 60% protein, 0% carbohydrate, 30% fat, 10% fiber), K4 (high-fat diet with a ratio of 45% protein, 0% carbohydrate, 45% fat, 10% fiber), K5 (high-fat diet with a ratio of 30% protein, 0% carbohydrate, 60% fat, 10% fiber) and K6 (high-fat diet on day 15 with a ratio of 15% protein, 0% carbohydrate, 75% fat, 10% fiber). The high-fat diet was administered for 28 days. The mean of tumor area delta at K1 (0.00 ± 0.00) mm2, K2 (3.52 ± 1.98) mm2, K3 (27.18 ± 21.23) mm2, K4 (13.19 ± 9.93) mm2, K5 (8.80 ± 1.72) mm2, K6 (10.81 ± 6.55) mm2, and (p=0.001). The mean of TNF-α levels at K1 (56.32 ± 8.25) ng/mL, K2 (65.99 ± 2.82) ng/mL, K3 (70.43 ± 4.61) ng/mL, K4 (58.05 ± 5.80) ng/mL, K5 (54.91 ± 3.27) ng/mL, K6 (59.67 ± 3.63) ng/mL and (P = 0.000). A high-fat diet lowers TNF-α levels and reduces the area of BZP-induced breast tumors. The lowest TNF-α levels and the lowest breast tumor area were found in groups with a fat: protein ratio = 60:30. Keywords: Benzopyrene induced, Breast tumor area, High-fat diet, Tumor necrosis factor-α

Moderate-to-vigorous physical activity (MVPA) has been shown to have a favorable effect on many diseases as a complementary therapy and is a critical component of healthy living. During the pandemic era, physical activity has been promoted for resistance against coronavirus disease 2019 (COVID-19). However, there is scarce evidence on whether MVPA could reduce the infectivity and susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The objective of this meta-analysis was to determine the effect of MVPA on morbidity, mortality, and duration of hospitalization in COVID-19 patients. We performed a comprehensive search of five online databases for eligible studies up to September 9, 2021. Meta-analyses were conducted to determine the association between MVPA and COVID-19-related morbidity, hospitalization, and mortality. The odds ratio (OR) was applied as the summary statistic for the primary outcomes. Secondary analyses were conducted to evaluate the difference in the metabolic equivalent of tasks (METs) between the outcome and non-outcome groups with the mean difference as the pooled effect. This meta-analysis included eight observational studies. We found that MVPA significantly reduced the odds of contracting SARS-CoV-2 infection (OR=0.88; 95% confidence interval [CI] = 0.85–0.92), hospitalization (OR=0.56; 95% CI=0.35–0.92), and mortality (OR=0.42; 95% CI=0.21–0.81) due to COVID-19 compared to no physical activity. METs≥500 min/week were linked to decreased morbidity and mortality of COVID-19 (OR=0.94 [95% CI=0.90–0.98]; OR=0.56 [95% CI=0.38–0.83]). COVID-19 patients with MVPA demonstrated a lower risk of COVID-19-related morbidity, hospitalization, and mortality compared to those who were less active, highlighting the importance of an active lifestyle despite the pandemic situation where such activities are limited.

Highlights: Vitamin D supplementations in different doses yield different outcomes. Multi-day vitamin D administration of 1000-6000 IU in patients with COVID-19 has more positive impacts than a single high dose of vitamin D. Patient morbidity, length of hospitalization, and patient mortality improved with multi-day vitamin D administration.   Abstract: This meta-analysis aimed to determine whether there is any optimal dose of vitamin D for morbidity, length of hospitalization, and mortality in patients with COVID-19. We conducted a comprehensive search in three online databases for eligible studies until February 28, 2022. Odds ratio (OR) and standardized mean difference (SMD) were applied as summary statistics of primary outcomes. The study quality of the literatures collected was assesed using the Cochrane risk of bias tool version 2 (RoB 2). Eight randomized clinical trials (RCT) were included in the study. In our analysis, we found that there was no significant difference in morbidity when vitamin D was administered to COVID-19 patients [OR=0.50 (95% CI=0.13-1.96); SMD=-0.14 (95% CI=-0.55-0.28)]. Duration of hospitalization [SMD=-0.12 (95% CI=-0.39-0.15)] and mortality [OR 0.47 (95% CI=0.19-1.17)] of COVID-19 patients in five studies also showed no significant difference compared to patients who do not take vitamin D. However, when we analyzed two other studies, we found that in patients who did not take vitamin D, mortality was lower [SMD=0.43 (95% CI=0.29, 0.58)]. Compared to a single high dose of vitamin D, the multi-day vitamin D administration of 1000-6000 IU in patients with COVID-19 resulted in improved patient morbidity, length of hospitalization, and patient mortality.